Gefitinib reduces oocyte quality by disturbing meiotic progression

Gefitinib is a first-line anti-cancer drug for the treatment of advanced non-small cell lung cancer (NSCLC). It has been reported that gefitinib can generate several drug-related adverse effects, including nausea, peripheral edema, decreased appetite and rash. However, the reproductive toxicity of gefitinib has not been clearly defined until now. Here we assessed the effects of gefitinib on oocyte quality by examining the critical events and molecular changes of oocyte maturation. Gefitinib at 1, 2, 5 or 10 mu M concentration was added to culture medium (M2). We found that gefitinib at its median peak concentration of 1 mu M did not affect oocyte maturation, but 5 mu M gefitinib severely blocked oocyte meiotic progression as indicated by decreased rates of germinal vesicle breakdown (GVBD) and polar body extrusion (PBE). We further showed that gefitinib treatment increased phosphorylation of CDK1 at the site of Try15, inhibited cyclin B1 entry into the nucleus, and disrupted normal spindle assembly, chromosome alignment and mitochondria dynamics, finally leading to the generation of aneuploidy and early apoptosis of oocytes. Our study reported here provides valuable evidence for reproductive toxicity of gefitinib administration employed for the treatment of cancer patients.

Automated summary

Gefitinib at a certain concentration does not affect oocyte maturation, but at another concentration severely blocks meiotic progression of oocytes. Treatment with gefitinib increases phosphorylation of CDK1 at the Try15 site, inhibits cyclin B1 entry into the nucleus, and disrupts normal spindle assembly, chromosome alignment, and mitochondria dynamics, ultimately leading to aneuploidy and early apoptosis of oocytes.